Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

Hyuncheol Chung, SunYoung Rha, Joon Oh Park, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, Jin Ju Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalBreast Cancer Research and Treatment
Volume49
Issue number1
DOIs
Publication statusPublished - 1998 Jun 29

Fingerprint

Urokinase Plasminogen Activator Receptors
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Premenopause
Breast Neoplasms
Postmenopause
Menstruation
Follicular Phase
Menopause
Neoplasms
Luteal Phase
Corpus Luteum
Tumor Burden
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{751e3b4de756443d9ff1328c3b488c08,
title = "Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients",
abstract = "The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.",
author = "Hyuncheol Chung and SunYoung Rha and Park, {Joon Oh} and Yoo, {Nae Choon} and Kim, {Joo Hang} and Roh, {Jae Kyung} and Min, {Jin Sik} and Lee, {Kyong Sik} and Kim, {Byung Soo} and Kim, {Jin Ju}",
year = "1998",
month = "6",
day = "29",
doi = "10.1023/A:1005997421733",
language = "English",
volume = "49",
pages = "41--50",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. / Chung, Hyuncheol; Rha, SunYoung; Park, Joon Oh; Yoo, Nae Choon; Kim, Joo Hang; Roh, Jae Kyung; Min, Jin Sik; Lee, Kyong Sik; Kim, Byung Soo; Kim, Jin Ju.

In: Breast Cancer Research and Treatment, Vol. 49, No. 1, 29.06.1998, p. 41-50.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

AU - Chung, Hyuncheol

AU - Rha, SunYoung

AU - Park, Joon Oh

AU - Yoo, Nae Choon

AU - Kim, Joo Hang

AU - Roh, Jae Kyung

AU - Min, Jin Sik

AU - Lee, Kyong Sik

AU - Kim, Byung Soo

AU - Kim, Jin Ju

PY - 1998/6/29

Y1 - 1998/6/29

N2 - The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.

AB - The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.

UR - http://www.scopus.com/inward/record.url?scp=15644369728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644369728&partnerID=8YFLogxK

U2 - 10.1023/A:1005997421733

DO - 10.1023/A:1005997421733

M3 - Article

VL - 49

SP - 41

EP - 50

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -